About H1N1 Vaccines
H1N1 influenza (zoonotic) is an infectious disease in humans caused by a variant of the swine H1N1 virus, known as H1N1v virus. The H1N1v virus is a contagious virus which infects nose, throat, and lungs. H1N1 virus is an RNA virus belonging to the Orthomyxoviridae family. Influenza A viruses infect different animal species such as humans, swine, birds, seals, and horses. Influenza A viruses can be subdivided on the basis of antigenicity of its surface glycoproteins neuraminidase and hemagglutinin. Hemagglutinin component is used by the virus to bind to host cell receptors. This facilitates viral entry into the host cell. Neuraminidase protein enzymatically cleaves terminal sialic acid residues from mucins, thereby allowing the virus to reach underlying cells in the respiratory tract. Elderly people, young children, and people with medical conditions including liver disorders, blood disorders, kidney disorders, chronic lung disease, asthma, and neurodevelopmental and neurological conditions are at a higher risk of getting infected. Influenza vaccines are administered for active immunization against influenza virus. This, in turn, confers protection against influenza disease. Vaccination of high-risk groups prevents unnecessary hospitalizations and premature deaths resulting due to influenza.
TechNavio's analysts forecast the Global H1N1 Vaccines market to grow at a CAGR of 5.40 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global H1N1 Vaccines market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of various vaccines administered to prevent human infection caused by H1N1 virus.
TechNavio's report, the Global H1N1 Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global H1N1 Vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• AstraZeneca
• GlaxoSmithKline
• Novartis
• Sanofi Pasteur
Other Prominent Vendors
• Baxter International
• bioCSL
• Mitsubishi Tanabe Pharma
• Protein Sciences Corporation
• Serum Institute of India
• Sinovac Biotech
• Zydus Cadila
Market Driver
• Increased Awareness on H1N1 Influenza
• For a full, detailed list, view our report
Market Challenge
• Antigenic Drift of H1N1v Virus
• For a full, detailed list, view our report
Market Trend
• Emergence of Quadrivalent Vaccines
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Route of Administration
08. WHO Recommendation
09. Key H1N1 Virus Vaccines for the 2013-2014 Season in the US
10. H1N1 Virus Vaccines Approved in the EU
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2013
19.3 Other Prominent Vendors
20. Key Vendor Analysis
20.1 AstraZeneca plc
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Business Segmentation
20.1.4 Business Strategy
20.1.5 Revenue by Business Segmentation
20.1.6 Revenue Comparison 2011-2013
20.1.7 Sales Revenue by Geographical Segmentation
20.1.8 Key Developments
20.1.9 SWOT Analysis
20.2 GlaxoSmithKline plc
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation
20.2.4 Business Segmentation by Revenue 2012 and 2013
20.2.5 Sales by Geography
20.2.6 Pipeline Products
20.2.7 Business Strategy
20.2.8 Key Information
20.2.9 SWOT Analysis
20.3 Novartis AG
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation by Revenue 2013
20.3.4 Business Segmentation by Revenue 2012 and 2013
20.3.5 Sales by Geography
20.3.6 Business Strategy
20.3.7 Key Developments
20.4 SWOT Analysis
20.5 Sanofi Pasteur
20.5.1 Key Facts
20.5.2 Business Overview
20.5.3 Business Strategy
20.5.4 Recent Developments
20.5.5 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global H1N1 Vaccines Market 2013-2018 (US$ million)
Exhibit 3: Global H1N1 Vaccines Market Segmentation by Route of Administration
Exhibit 4: Global H1N1 Vaccines Market Segmentation by Route of Administration 2013
Exhibit 5: Global H1N1 Vaccines Market by Geographical Segmentation 2013
Exhibit 6: Global H1N1 Vaccines Market Share Analysis 2013
Exhibit 7: Sanofi Pasteur's Influenza Vaccine Segmentation by Geography 2013
Exhibit 8: Sales of Fluarix/FluLaval by Geography 2013
Exhibit 9: Sales of FluMist/Fluenz by Geography 2013
Exhibit 10: AstraZeneca plc: Business Segmentation
Exhibit 11: AstraZeneca plc: Revenue by Business Segmentation2013
Exhibit 12: AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 13: AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
Exhibit 14: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 15: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 16: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 17: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 18: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 19: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 20: Novartis AG: Sales by Geography 2013
